The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).
Suresh S. Ramalingam
Consultant or Advisory Role - Synta (U)
Glenwood D. Goss
Consultant or Advisory Role - Synta (U)
Zoran Gojko Andric
No relevant relationships to disclose
Igor Bondarenko
No relevant relationships to disclose
Bojan Zaric
Consultant or Advisory Role - Synta
Honoraria - Synta
Timur Ceric
No relevant relationships to disclose
Elena Vladimir Poddubskaya
No relevant relationships to disclose
Tudor-Eliade Ciuleanu
No relevant relationships to disclose
James F. Spicer
No relevant relationships to disclose
Enriqueta Felip
No relevant relationships to disclose
Vera Hirsh
No relevant relationships to disclose
Christian Manegold
Honoraria - Synta
Rafael Rosell
No relevant relationships to disclose
Fadlo Raja Khuri
No relevant relationships to disclose
Vojislav M. Vukovic
Employment or Leadership Position - Synta
Stock Ownership - Synta
Florentina Teofilovici
Employment or Leadership Position - Synta
Iman El-Hariry
Employment or Leadership Position - Synta
Stock Ownership - Synta
Wei Guo
Employment or Leadership Position - Synta
Stock Ownership - Synta
Safi R. Bahcall
Employment or Leadership Position - Synta
Stock Ownership - Synta
Dean Fennell
Consultant or Advisory Role - Synta
Honoraria - Synta
Research Funding - Synta